Intravitreal injection of methotrexate in an experimental rabbit model: Determination of pharmacokinetics

Ozkan, Ebru Bener; Ozcan, Altan A.; Alparslan, Nazan
May 2011
Indian Journal of Ophthalmology;May2011, Vol. 59 Issue 3, p197
Academic Journal
Purpose: To investigate the pharmacokinetics of intravitreally administered methotrexate. Materials and Methods: Twenty-one New Zealand white rabbits were used in the study. The pharmacokinetics of intravitreally injected 800 μg/0.1 ml of methotrexate was investigated. Intravitreal concentration of the drug was measured at seven different times, in six eyes at each occasion, on a total of 42 eyes of 21 rabbits from a period of 30 minutes to 72 hours. Results: The volume of distribution was calculated as 1.33 ml following intravitreal injection of 800 μg methotrexate. Vitreous concentrations of the drug were found to be decreasing related to the specific mathematical equation; drug concentration= 1426.73 e-0.1182(time) and remained over effective dose by 81 hours with a half life of 5.9 hours. Conclusions: These findings evidenced those vitreous levels of methotrexate at various time intervals after 800 μg intravitreal injections which formulated a mathematical equation for calculation of vitreous level of the drug at each hour.


Related Articles

  • Clinical pharmacokinetics of mycophenolate mofetil. Bullingham, R.E.S.; Nicholls, A.J.; Kamm, B.R.; Bullingham, R E // Clinical Pharmacokinetics;1998, Vol. 34 Issue 6, p429 

    The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral administration, mycophenolate mofetil was rapidly and completely absorbed, and underwent extensive presystemic...

  • Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. David-Neto, Elias; Araujo, Lilian Monteiro Pereira; Sumita, Nairo Massakazu; Mendes, Maria Elizabeth; Ribeiro Castro, Maria Cristina; Alves, Cristiane Feres; Kakehashi, Erica; Romano, Paschoalina; Yagyu, Elisa Midori; Queiroga, Margaret; Nahas, William Carlos; Ianhez, Luiz Estevam // Pediatric Nephrology;Mar2003, Vol. 18 Issue 3, p266 

    Mycophenolate mofetil (MMF) is given to children in fixed doses based either on body weight or body surface area. There are data indicating mycophenolic acid (MPA) blood levels should be monitored in the early period of transplantation. However, there is little information regarding MPA...

  • Medication Safety and Reliability. New contraindications and modified cardiovascular monitoring parameters for fingolimod.  // Formulary;Jun2012, Vol. 47 Issue 6, p227 

    The article reports on a May 15, 2012 announcement from the U.S. Food and Drug Administration. In the announcement the agency indicated that it had concluded a safety review of the drug fingolimod and discussed contraindications which were added to the drug's label as a result of the review.

  • Time of day of taking immunosupressive agents after renal transplantation: a possible influence on graft survival. Knapp, M.S.; Byrom, N.P.; Pownall, R.; Mayor, P. // British Medical Journal;11/22/1980, Vol. 281 Issue 6252, p1382 

    Examines the influence of the time of immunosuppressive administration on graft survival after renal transplantation in Great Britain. Factors affecting renal transplantation outcome; Incidence of graft rejection in several patients; Considerations in drug administration.

  • CELL BIOLOGY - IMMUNOLOGY - PATHOLOGY Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity. Shihab, Fuad S.; Bennett, William M.; Yi, Hong; Choi, Seung-Ok; Andoh, Takeshi F. // Kidney International;Apr2004, Vol. 65 Issue 4, p1262 

    Sirolimus increases transforming growth factor-β1 expression and potentiates chronic cyclosporine nephrotoxicity. Background. Sirolimus (SRL) is increasingly being used to decrease cyclosporine (CsA) exposure. SRL is not known to be nephrotoxic and has a mechanism of action distinct from CsA....

  • Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. Christians, U.; Jacobsen, W.; Benet, L.Z.; Lampen, A. // Clinical Pharmacokinetics;2002, Vol. 41 Issue 11, p813 

    The clinical management of tacrolimus, a macrolide used as immunosuppressant after transplantation, is complicated by its narrow therapeutic index in combination with inter- and intraindividually variable pharmacokinetics. As a substrate of cytochrome P450 (CYP) 3A enzymes and P-glycoprotein,...

  • Clinical pharmacokinetics of cyclophosphamide. de Jonge, Milly E.; Huitema, Alwin D. R.; Rodenhuis, Sjoerd; Beijnen, Jos H. // Clinical Pharmacokinetics;2005, Vol. 44 Issue 11, p1135 

    Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of...

  • Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. van Giershergen, Paul L. M.; Bodin, Frédéric; Dingemanse, Jasper // European Journal of Clinical Pharmacology;Jul2002, Vol. 58 Issue 4, p243 

    Objective. To investigate in 12 healthy subjects the pharmacokinetics and tolerability of tezosentan, an endothelin receptor antagonist, when given concomitantly with cyclosporin. Methods. Tezosentan was infused at a dose of 6.25 mg/h and 25 mg/h for 6 h either alone or following a single dose...

  • The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Grinyó, Josep M.; Ekberg, Henrik; Mamelok, Richard D.; Oppenheimer, Federico; Sánchez-Plumed, Jaime; Gentil, Miguel Angel; Hernandez, Domingo; Kuypers, Dirk R.; Brunet, Mercé // Nephrology Dialysis Transplantation;Jul2009, Vol. 24 Issue 7, p2269 

    Background. Exposure to mycophenolic acid (MPA), the primary active metabolite of mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies depending on the concomitantly administered immunosuppressive drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics